Gout News

Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence with the recommended dosages of urate-lowering therapies, according to survey data.

Targeted therapies for active inflammatory arthritis should be started “without delay” for patients with cancer in remission, according to new EULAR points to consider published in Annals of the Rheumatic Diseases.

Colchicine for gout flare prophylaxis reduces the risk for cardiovascular events among patients initiating urate-lowering therapy, according to data published in The Lancet Rheumatology.

WASHINGTON — SGLT2 inhibitors can reduce the need for urate-lowering and flare therapies, and lower the odds of gout-centric medical visits, in patients with gout alongside type 2 diabetes, according to a speaker at ACR Convergence 2024.

WASHINGTON — The use of colchicine for gout flare prevention imparts a “modest” decrease in the risk for knee or hip replacement over several years, according to a study presented at ACR Convergence 2024.

WASHINGTON — Among patients with systemic autoimmune rheumatic diseases, circulating interleukin-18 levels were lower in those with long COVID vs. those without, according to data presented at ACR Convergence 2024.

WASHINGTON — Different stages of gout treatment may call for different serum urate targets, with certain levels being better for dissolving or preventing monosodium urate crystals, according to data presented at ACR Convergence 2024.

A genetic predisposition for gout predicts an increased risk for cardiovascular disease, but a healthy lifestyle can curb that risk, according to data published in RMD Open.

Machine learning can be combined with Raman spectroscopy to objectively identify gout-causing crystals in synovial fluid and diagnose the condition with high certainty, according to data published in Rheumatology.